NCT02215967: Phase 1 - Study of T Cells Targeting B-Cell Maturation Antigen for RRMM
Updated: Apr 26, 2022
NCT02215967: Phase 1 - Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma
Background: - T cells are white blood cells that fight several cancers. One cancer therapy involves removing a persons' T cells, changing them in a lab, and then returning them to the person. Researchers want to see if this helps people with multiple myeloma.
Objective: - To test the safety of giving anti-B-Cell Maturation Antigen T cells to people with multiple myeloma.
Sponsor: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT02215967
Official Title: A Phase I Clinical Trial of T-Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma
Click here for details on Clinicaltrials.gov
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells
J Clin Oncol; 2018 Aug
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma